A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer.
Iain R Macpherson,
Pavlina Spiliopoulou,
Saeed Rafii,
Matilde Saggese,
Richard D Baird,
Javier Garcia-Corbacho,
Antoine Italiano,
Jacques Bonneterre,
Mario Campone,
Nicola Cresti,
John Posner,
Yousuke Takeda,
Akinori Arimura,
James Spicer
Jan 20, 2020
BACKGROUND: Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4. This trial evaluated the safety, tolerability, pharmacokinetics and antitumour activity of daily oral epertinib combined with trastuzumab...